Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Eli Lilly Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (73)
Cancellation by sponsor (67)
Prescription medicine registration (21)
Australian public assessment report (AusPar) (20)
Designation or determination (4)
Prescription medicine decision summary (4)
Prescription medicine evaluation (4)

Date

2026 (6)
2025 (28)
2024 (21)
2023 (21)
2022 (15)
2021 (10)
2020 (4)
2019 (34)
2018 (14)
2017 (1)
2016 (2)
2015 (7)
2014 (2)
2013 (4)
2012 (1)
2011 (2)
2010 (1)
2008 (2)
2007 (1)
2006 (1)
2004 (1)
2002 (2)
1999 (4)
1998 (1)
1996 (2)
1992 (4)
1991 (2)

Search

Sponsor content

193 result(s) found, displaying 131 to 140

OLANZAPINE LY olanzapine 2.5mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
OLANZAPINE LY olanzapine 5mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
OLANZAPINE LY olanzapine 7.5mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
RELADDIN pemetrexed (as disodium) 100 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
RELADDIN pemetrexed (as disodium) 500mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
OLANZAPINE LY WAFER olanzapine 5mg wafer blister pack Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
OLANZAPINE LY IM olanzapine 10mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
OLANZAPINE LY WAFER olanzapine 10mg wafer blister pack Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
RALOXIFENE LY raloxifene hydrochloride 60mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
EMGALITY (Eli Lilly Australia Pty Ltd)

22 May 2019

Prescription medicine registration

Active ingredients: galcenezumab.

Pages

First page
Previous page
…
Page 10
Page 11
Page 12
Page 13
Current page 14
Page 15
Page 16
Page 17
Page 18
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.